MyMD-1改善老年小鼠健康跨度并延长寿命:与雷帕霉素的非劣效性研究
该研究在19月龄C57BL/6小鼠中比较MyMD-1与雷帕霉素对寿命和健康跨度的影响,并体外比较两者对12种人原代细胞系统148种生物标志物的作用。MyMD-1组寿命显著长于雷帕霉素组,且体重下降更轻、肌力更强、衰弱进展更慢;体外MyMD-1具抗增殖、抗炎和抗纤维化特性,对促炎和促纤维化标志物抑制更强。
要点
- 在老年小鼠中,MyMD-1延长寿命优于高剂量和低剂量雷帕霉素。
- MyMD-1改善健康跨度:体重下降更轻、肌力更强、衰弱进展更慢。
- 体外MyMD-1抗炎和抗纤维化活性强于雷帕霉素。
核心结论
- MyMD-1在老年小鼠中延长寿命优于雷帕霉素,并改善多项健康跨度指标。
- MyMD-1通过调节炎症和组织重塑发挥有益作用,体外对促炎和促纤维化标志物抑制更强。
研究设计与样本
- 体内研究:54只19月龄C57BL/6小鼠随机接受MyMD-1、高剂量雷帕霉素(126 ppm)或低剂量雷帕霉素(14 ppm)联合二甲双胍,每组18只(10雌8雄),随访16个月或至死亡。
- 体外研究:使用12种人原代细胞系统(BioMAP Diversity PLUS)比较MyMD-1与雷帕霉素,共检测148种生物标志物。
主要发现
- 在校正性别及血清IL-6、TNF-α和IL-17A水平的Cox生存模型中,MyMD-1组寿命显著长于高剂量雷帕霉素组(p = .019)和低剂量雷帕霉素组(p = .01)。
- MyMD-1组体重下降更轻、肌力更强、向衰弱进展更慢。
- 体外MyMD-1具抗增殖、抗炎和抗纤维化特性,许多与雷帕霉素共享,但对促炎和促纤维化标志物抑制更强。
关键数值与推荐
- 高剂量雷帕霉素为126 ppm,低剂量雷帕霉素为14 ppm并联合二甲双胍。
- 寿命比较采用Cox生存模型,校正性别和血清IL-6、TNF-α、IL-17A水平;MyMD-1 vs 高剂量雷帕霉素p = .019,vs 低剂量雷帕霉素p = .01。
- 体外使用BioMAP Diversity PLUS panel,包含12种人原代细胞系统和148种生物标志物。
临床怎么用
- 目前仅为动物和体外研究,尚不能直接用于老年临床实践。
- 提示靶向炎症通路(如TNF-α)可能同时改善健康跨度和寿命,值得进一步转化研究。
局限性
- 研究仅在小鼠和体外细胞系统进行,尚未在人体验证。
- 样本量有限(每组18只小鼠),随访16个月或至死亡。
- 低剂量雷帕霉素组联合二甲双胍,与单药雷帕霉素组不完全对等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aging and age-related diseases represent a compelling therapeutic goal for senolytics and drugs targeting inflammatory or metabolic pathways. We compared MyMD-1, a synthetic derivative of the alkaloid myosmine capable of suppressing TNF-α production, to rapamycin, the best characterized drug endowed with antiaging properties. In vivo, a longitudinal cohort of 54 C57BL/6 mice, 19-month-old at the start, was randomized to receive MyMD-1, high-dose (126 ppm) rapamycin, or low-dose (14 ppm) rapamycin plus metformin. Each treatment arm included 18 mice (10 females and 8 males) and was followed for 16 months or until death. Life span was significantly longer in MyMD-1 than rapamycin (p = .019 vs high-dose and .01 vs low-dose) in a Cox survival model that accounted for sex and serum levels of IL-6, TNF-α, and IL-17A. MyMD-1 also improved several health span characteristics, resulting in milder body weight loss, greater muscle strength, and slower progression to frailty. In vitro, MyMD-1 and rapamycin were compared using a panel of 12 human primary cell systems (BioMAP Diversity PLUS), where a total of 148 biomarkers were measured. MyMD-1 possessed antiproliferative, anti-inflammatory, and antifibrotic properties. Many were shared with rapamycin, but MyMD-1 was more active in the inhibition of proinflammatory and profibrotic biomarkers. Overall, MyMD-1 emerges as a new compound that, even when begun at an advanced age, induces beneficial effects on health and life span by modulating inflammation and tissue remodeling.
引用
- Sabini E, O'Mahony A, Caturegli P, et al. MyMD-1 Improves Health Span and Prolongs Life Span in Old Mice: A Noninferiority Study to Rapamycin. J Gerontol A Biol Sci Med Sci. 2023. PMID: 35914953. doi:10.1093/gerona/glac142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。